CD4 T Cell Survival Following Intermittent IL-2 Therapy is Predictive of Increase in CD4 T Cell Count in HIV-Infected Patients

Administration of IL-2 to HIV-infected patients leads to significant increases in CD4 T cell counts. Previously we have shown that IL-2 induces increased proliferation and survival of CD4 T cells. Deuterium labeling studies were undertaken to study the relationship between IL-2 induced increases in CD4 T cell numbers and IL-2 effects on cell proliferation and survival. A strong inverse correlation was seen between the decay rate of label in CD4 cells and increases in CD4 cell numbers (R= -0.67; p<0.001). This correlation was not seen with the level of proliferating cells. Although the baseline CD4 cell count and number of CD4 cells expressing CD25 were also

[1]  R. Dersimonian,et al.  CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation. , 2007, The Journal of infectious diseases.

[2]  B. Gazzard,et al.  Predictors of CD4 count change over 8 months of follow up in HIV‐1‐infected patients with a CD4 count≥300 cells/μL who were assigned to 7.5 MIU interleukin‐2 , 2007, HIV medicine.

[3]  Douglas A. Hosack,et al.  Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. , 2005, The Journal of clinical investigation.

[4]  J. Metcalf,et al.  In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. , 2005, The Journal of clinical investigation.

[5]  R. Lempicki,et al.  IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. , 2004, Blood.

[6]  N. Markowitz,et al.  Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  H. Lane,et al.  A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100-300 CD4+ T cells. , 2003, Clinical immunology.

[8]  C. Hallahan,et al.  Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. , 2002, Blood.

[9]  Alan S. Perelson,et al.  Modeling deuterated glucose labeling of T-lymphocytes , 2002, Bulletin of mathematical biology.

[10]  Richard A. Lempicki,et al.  Identification of Dynamically Distinct Subpopulations of T Lymphocytes That Are Differentially Affected by HIV , 2001, The Journal of experimental medicine.

[11]  J. Kahn,et al.  Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. , 2000, JAMA.

[12]  M. Hellerstein,et al.  Measurement of T-cell kinetics: recent methodologic advances. , 1999, Immunology today.

[13]  É. Oksenhendler,et al.  Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial , 1999, The Lancet.

[14]  R. Dewar,et al.  A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. , 1999, The Journal of infectious diseases.

[15]  J. Metcalf,et al.  Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. , 1996, The New England journal of medicine.

[16]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .